$0.77 0.00 (0.20%) Catalyst Pharmaceuticals Inc - NASDAQ

Jul. 22, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 0.77
Trade Time: Jul 22 04:00 PM Eastern Daylight Time
Change: +0.00 (0.20%)
Prev Close: 0.76
Open: 0.78
Bid: 0.77
Ask: 0.77
  1. No results found.
  1. Mid-Afternoon Market Update: Dow Gains Over 250 Points; Catalyst Pharmaceuticals Shares Slide

    Benzinga | Feb. 17, 2016 | 14:34PM EST
  2. Mid-Day Market Update: Crude Oil Surges 5%; Fossil Group Shares Rise On Strong Results

    Benzinga | Feb. 17, 2016 | 12:02PM EST
  3. Catalyst Pharmaceuticals Crashes 50% Following 'Refusal To File' Letter From FDA

    Benzinga | Feb. 17, 2016 | 10:16AM EST
  4. Catalyst Pharmaceuticals Announces a Clinical Trial for Pediatric Patients With Congenital Myasthenic Syndromes

    Benzinga | Oct. 6, 2015 | 08:06AM EST
  5. Mid-Morning Market Update: Markets Open Lower; Lennar Beats Q2 Estimates

    Benzinga | Jun. 24, 2015 | 10:20AM EST
  6. Catalyst Pharmaceuticals Announces Oral Presentation of Firdapse Phase 3 Trial Data at American Academy of Neurology Annual Meeting (AAN)

    Benzinga | Apr. 14, 2015 | 08:15AM EST
  7. Piper Jaffray Remains Bullish on Catalyst Pharmaceuticals Following the Close of its Recent ...

    GuruFocus | Feb. 17, 2015 | 16:26PM EST
  8. Weekly CEO Buys Highlight: BH, CLMS, OPK, GPC, CPRX

    GuruFocus | Jan. 18, 2015 | 07:46AM EST
  9. Weekly CEO Buys Highlight: BH, CLMS, OPK, CPRX, BRT

    GuruFocus | Jan. 12, 2015 | 10:21AM EST
  10. Catalyst Pharmaceuticals Announces Proposed Settlement Of Pending Securities Class Action Lawsuit

    Benzinga | Nov. 4, 2014 | 08:08AM EST
  11. Midday Gainers From October 8 - GT Advanced Technologies Inc, Unilife Corp And More

    Benzinga | Oct. 8, 2014 | 13:11PM EST
  12. Catalyst Pharmaceuticals to Present Top-Line Safety And Efficacy Results From Phase 3 Firdapse Trial At 139th Annual Meeting Of The American Neurological Association

    Benzinga | Oct. 8, 2014 | 08:04AM EST
  13. Morning Market Movers

    Benzinga | Sep. 30, 2014 | 09:37AM EST
  14. Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115

    Benzinga | Sep. 2, 2014 | 08:04AM EST
  15. Catalyst Pharmaceutical Partners Provides Updates On Progress of Phase 3 Firdapse Study In Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)

    Benzinga | Aug. 11, 2014 | 08:05AM EST
Trading Center